Searchable abstracts of presentations at key conferences in endocrinology

ea0020p182 | Endocrine tumours and neoplasia | ECE2009

Endocrine gland-derived vascular endothelial growth factor and its receptors in adrenocortical carcinoma

Sbiera Silviu , Kuehner Dorothee , Wortmann Sebastian , Adam Patrick , Voelker Hans-Ullrich , Kraus Luitgard , Beyer Melanie , Quinkler Markus , Willenberg Holger , Weismann Dirk , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF; also termed prokineticin-1) has been identified as a mitogen preferable for the endothelium of steroidogenic glands (1). EG-VEGF and its receptors (prokineticin receptors 1 and 2; PKR1 and 2) are highly expressed in the normal adrenal gland and an autocrine mitogenic loop has been proposed (2). Therefore, we investigated the expression of EG-VEGF and its receptors in adrenocortical carcinoma (ACC)...

ea0056gp24 | Adrenal clinical | ECE2018

Germline CYP2W1*6 polymorphism is a new predictive marker of sensitivity to mitotane treatment in advanced adrenocortical carcinoma: a multicenter European study

Altieri Barbara , Herterich Sabine , Volante Marco , Sbiera Silviu , De Francia Silvia , Casa Silvia Della , Pontecorvi Alfredo , Quinkler Markus , Kienitz Tina , Mannelli Massimo , Canu Letizia , Chortis Vasileios , Kaltsas Gregory , Kroiss Matthias , Terzolo Massimo , Fassnacht Martin , Ronchi Cristina L

The cytochrome P450 2W1 (CYP2W1) is an orphan enzyme able to activate anticancer pro-drugs and to metabolise endogenous substances as fatty acids and lysophospholipids. Aim of the study was to evaluate the frequency of CYP2W1 polymorphisms in patients with adrenocortical carcinoma (ACC) and correlate it with the sensitivity to mitotane, which represents the only approved drug for the treatment of advanced ACC.Methods: A multicenter retrospective study in...